Enter your email address to receive updates
Search By Trade Name
Trade name | Generic name | Classification
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z 
Generic Name
Trade Name
Cytarabine Injection
pharmacia & upjhon
Risk Category
  • Positive evidence of human fetal risk exists.
  • Potential benefits may warrant use of the drug in pregnant women despite potential risks (e.g. life threatening situations or serious illness).
FDA Pregnancy Risk Categories

Place (not click) your mouse cursor over the bold words in the text below to receive description

  • antineoplastic.
  • Fetal Risk
    Fetal Risk
  • Exposure to cytarabine combination therapy during pregnancy may cause intrauterine growth retardation, and fetal death.
  • Use of cytarabine with other antineoplastic in the third trimester may cause neonatal pancytopenia.
  • Use of the drug in the first half of pregnancy is associated with congenital and chromosomal abnormalities including: Trisomies, chromosomal gaps and rings, ear limb and digital defects.
  • Doubtful associaiton between paternal use of the drug and fetal congenital anomalies including: Tetralogy of fallot, anencephaly, syndactyly and still birth.
  • Occupational exposure of pregnant women to antineoplastic drugs carries risk to the fetus including fetal loss and malformations.
  • Breast Feeding
    Breast Feeding
  • No data available.
  • Other Trade Names
    The information on this Web site is not intended as a substitute for the advice and care of your doctor or other health-care provider. Always consult your doctor if you have any questions about exposures during pregnancy and lactation, and before you take any medications. Please read the Terms and Conditions before using this website.
      Tell A Friend

        Your Friend
     2   +   2    =  
      Calculate Birth Date
    Enter the first day of the last menstruation
    Month Day Year
    Month Day Year